Radionuclide Drug Conjugates (RDCs)
Radionuclide Drug Conjugates (RDCs) revolutionize cancer treatment by combining effective therapy with precise targeting, minimizing side effects. RDCs consist of four key components: a radionuclide for therapeutic or diagnostic radiation, a targeting molecule to guide delivery, a chelator to securely bind the radionuclide, and a linker to connect the components. The chelator and linker ensure RDC stability and safety, directing treatment to diseased cells while protecting healthy tissue. We offer an extensive inventory of chelators and linkers to expedite your drug discovery initiatives.
| Product Name | CAS | Molecular Formula | Molecular Weight | Purity | Structure |
Consulting hotline
Address：Wuhan
E-mail：sales@affinitytech.cn
Telephon：027-59822217
Telephon：0411-39805809
Mobile Phone：15841022315
WeChat official account
